HRP20130080T1 - Inhibitori histonske deacetilaze sa spojenom aktivnosti protiv histonskih deacetilaza klase-i i klase-iib u kombinaciji sa inhibitorima proteasoma - Google Patents
Inhibitori histonske deacetilaze sa spojenom aktivnosti protiv histonskih deacetilaza klase-i i klase-iib u kombinaciji sa inhibitorima proteasoma Download PDFInfo
- Publication number
- HRP20130080T1 HRP20130080T1 HRP20130080TT HRP20130080T HRP20130080T1 HR P20130080 T1 HRP20130080 T1 HR P20130080T1 HR P20130080T T HRP20130080T T HR P20130080TT HR P20130080 T HRP20130080 T HR P20130080T HR P20130080 T1 HRP20130080 T1 HR P20130080T1
- Authority
- HR
- Croatia
- Prior art keywords
- drug
- resistant
- leukemia
- acute
- combination
- Prior art date
Links
- 229940079156 Proteasome inhibitor Drugs 0.000 title claims 5
- 239000003207 proteasome inhibitor Substances 0.000 title claims 5
- 229940121372 histone deacetylase inhibitor Drugs 0.000 title claims 4
- 239000003276 histone deacetylase inhibitor Substances 0.000 title claims 4
- 102000003964 Histone deacetylase Human genes 0.000 title 1
- 108090000353 Histone deacetylase Proteins 0.000 title 1
- 229940079593 drug Drugs 0.000 claims 15
- 239000003814 drug Substances 0.000 claims 15
- 208000031261 Acute myeloid leukaemia Diseases 0.000 claims 4
- 208000032791 BCR-ABL1 positive chronic myelogenous leukemia Diseases 0.000 claims 4
- 208000010833 Chronic myeloid leukaemia Diseases 0.000 claims 4
- 208000033761 Myelogenous Chronic BCR-ABL Positive Leukemia Diseases 0.000 claims 4
- 208000033776 Myeloid Acute Leukemia Diseases 0.000 claims 4
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 4
- 229960001467 bortezomib Drugs 0.000 claims 4
- 206010025323 Lymphomas Diseases 0.000 claims 3
- 208000034578 Multiple myelomas Diseases 0.000 claims 3
- 206010035226 Plasma cell myeloma Diseases 0.000 claims 3
- 150000001875 compounds Chemical class 0.000 claims 3
- 208000024893 Acute lymphoblastic leukemia Diseases 0.000 claims 2
- 208000014697 Acute lymphocytic leukaemia Diseases 0.000 claims 2
- 206010000871 Acute monocytic leukaemia Diseases 0.000 claims 2
- 208000036762 Acute promyelocytic leukaemia Diseases 0.000 claims 2
- 208000032800 BCR-ABL1 positive blast phase chronic myelogenous leukemia Diseases 0.000 claims 2
- 208000004860 Blast Crisis Diseases 0.000 claims 2
- 208000031422 Lymphocytic Chronic B-Cell Leukemia Diseases 0.000 claims 2
- 208000035489 Monocytic Acute Leukemia Diseases 0.000 claims 2
- 208000006664 Precursor Cell Lymphoblastic Leukemia-Lymphoma Diseases 0.000 claims 2
- 208000033826 Promyelocytic Acute Leukemia Diseases 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 150000003839 salts Chemical class 0.000 claims 2
- 208000011691 Burkitt lymphomas Diseases 0.000 claims 1
- 108010033040 Histones Proteins 0.000 claims 1
- PAWIYAYFNXQGAP-UHFFFAOYSA-N N-hydroxy-2-[4-[[(1-methyl-3-indolyl)methylamino]methyl]-1-piperidinyl]-5-pyrimidinecarboxamide Chemical compound C12=CC=CC=C2N(C)C=C1CNCC(CC1)CCN1C1=NC=C(C(=O)NO)C=N1 PAWIYAYFNXQGAP-UHFFFAOYSA-N 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000003112 inhibitor Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 1
- 229950010654 quisinostat Drugs 0.000 claims 1
- 210000004881 tumor cell Anatomy 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/05—Dipeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Claims (8)
1. Kombinacija, naznačena time, da sadrži inhibitor proteasoma, pri čemu je navedeni inhibitor proteasoma bortezomib, te inhibitor histonske deacetilaze, pri čemu je navedeni inhibitor histonske deacetilaze spoj br. 1a (JNJ26481585)
[image]
njegove farmaceutski prihvatljive kisele i bazne adicijske soli i stereokemijski izomerni oblici.
2. Kombinacija prema zahtjevu 1, naznačena time, da je u obliku farmaceutskog pripravka koji sadrži bortezomib i spoj br. 1a zajedno sa jednim ili više farmaceutskih nosača.
3. Kombinacija prema zahtjevu 2, naznačena time, da je za istovremenu, odvojenu ili slijednu uporabu.
4. Kombinacija prema zahtjevima 1 do 3, naznačena time, da se koristi u medicinskom liječenju.
5. Uporaba kombinacije prema bilo kojem od zahtjeva 1 ili 2, naznačena time, da se koristi u proizvodnji lijeka za inhibiciju rasta tumorskih stanica.
6. Upotreba inhibitora histonske deacetilaze u kombinaciji sa inhibitorom proteasoma, naznačena time, da se koristi u proizvodnji lijeka za liječenje akutne limfoblastne leukemije, akutne mijelogene leukemije, akutne promijelocitne leukemije, akutne mijeloidne leukemije, akutne monocitne leukemije, limfoma, kronične leukemije B-stanica, kronične mijeloidne leukemije, kronične mijeloidne leukemije kod blastične krize, Burkittovog limfoma i multiplog mijeloma pri čemu je navedeni inhibitor histonske deactilaze spoj br. 1a
[image]
njegove farmaceutski prihvatljive kisele i bazne adicione soli i stereokemijski izomerni oblici,
te pri čemu je navedeni inhibitor proteasoma, bortezomib.
7. Uporaba prema zahtjevu 6, naznačena time, da se navedeni lijek koristi za liječenje akutne limfoblastne leukemije koja je rezistentna na lijekove, akutne mijelogene leukemije koja je rezistentna na lijekove, akutne promijelocitne leukemije koja je rezistentna na lijekove, akutne mijeloidne leukemije koja je rezistentna na lijekove, akutne monocitne leukemije koja je rezistentna na lijekove, limfoma rezistentnog na lijekove, kronične leukemije B-stanica koja je rezistentna na lijekove, kronične mijeloidne leukemije koja je rezistentna na lijekove, kronične mijeloidne leukemije kod blastične krize koja je rezistentna na lijekove, Burkittovog limfoma rezistentnog na lijekove i multiplog mijeloma koji je rezistentan na lijekove.
8. Uporaba prema zahtjevima 6 i 7, naznačena time, da je navedeni lijek namijenjen za liječenje multiplog mijeloma koji je rezistentan na bortezomib.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP06120726 | 2006-09-15 | ||
| US91589507P | 2007-05-03 | 2007-05-03 | |
| PCT/EP2007/059518 WO2008031817A2 (en) | 2006-09-15 | 2007-09-11 | Histone deacetylase inhibitors with combined activity on class-i and class-iib histone deacetylases in combination with proteasome inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20130080T1 true HRP20130080T1 (hr) | 2013-02-28 |
Family
ID=38824548
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20130080TT HRP20130080T1 (hr) | 2006-09-15 | 2013-01-30 | Inhibitori histonske deacetilaze sa spojenom aktivnosti protiv histonskih deacetilaza klase-i i klase-iib u kombinaciji sa inhibitorima proteasoma |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US20090312284A1 (hr) |
| EP (1) | EP2066327B1 (hr) |
| JP (1) | JP5185274B2 (hr) |
| KR (1) | KR101489947B1 (hr) |
| AU (1) | AU2007296256B2 (hr) |
| CA (1) | CA2659070C (hr) |
| EA (1) | EA020276B1 (hr) |
| HK (1) | HK1136770A1 (hr) |
| HR (1) | HRP20130080T1 (hr) |
| IL (1) | IL197426A (hr) |
| MX (1) | MX2009002925A (hr) |
| PL (1) | PL2066327T3 (hr) |
| WO (1) | WO2008031817A2 (hr) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1611088T1 (sl) | 2003-04-07 | 2009-12-31 | Pharmacyclics Inc | Hidroksamati kot terapevtska sredstva |
| US8603521B2 (en) * | 2009-04-17 | 2013-12-10 | Pharmacyclics, Inc. | Formulations of histone deacetylase inhibitor and uses thereof |
| WO2012008514A1 (ja) * | 2010-07-15 | 2012-01-19 | シャープ株式会社 | 画像のイントラ予測モード推定装置、画像符号化装置、画像復号装置、及び画像の符号化データ |
| WO2013021032A1 (en) | 2011-08-11 | 2013-02-14 | Janssen Pharmaceutica Nv | Histone deacetylase inhibitors in combination with proteasome inhibitors and dexamethasone |
| CN103917231B (zh) | 2011-09-13 | 2016-09-28 | 药品循环有限责任公司 | 组蛋白脱乙酰酶抑制剂与苯达莫司汀的联合制剂及其用途 |
| EP2827861A4 (en) * | 2012-03-19 | 2016-03-16 | Aposignal Bioscience Llc | COMPOSITION AND METHODS FOR CELLULAR MODULATION |
| TWI649081B (zh) | 2013-08-02 | 2019-02-01 | 製藥公司 | 治療固態腫瘤之方法 |
| KR102002581B1 (ko) * | 2016-10-04 | 2019-07-22 | 주식회사 종근당 | 혈액암 치료를 위한 hdac 저해제 및 프로테아좀 억제제 또는 면역조절성 약물을 포함하는 약학적 조합물 |
| CN110314222B (zh) * | 2019-08-07 | 2023-05-26 | 上海交通大学医学院附属瑞金医院 | 硼替佐米和帕比司他或伏立诺他的组合物在制备治疗耐药型mll白血病的药物中的应用 |
| CN112029738B (zh) * | 2020-08-18 | 2022-04-29 | 浙江省人民医院 | 人parkin蛋白乙酰化及其在药物制备中的应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6083903A (en) * | 1994-10-28 | 2000-07-04 | Leukosite, Inc. | Boronic ester and acid compounds, synthesis and uses |
| WO2006010750A1 (en) * | 2004-07-28 | 2006-02-02 | Janssen Pharmaceutica N.V. | Substituted indolyl alkyl amino derivatives as novel inhibitors of histone deacetylase |
-
2007
- 2007-09-11 EA EA200970284A patent/EA020276B1/ru unknown
- 2007-09-11 WO PCT/EP2007/059518 patent/WO2008031817A2/en active Application Filing
- 2007-09-11 AU AU2007296256A patent/AU2007296256B2/en active Active
- 2007-09-11 PL PL07803397T patent/PL2066327T3/pl unknown
- 2007-09-11 JP JP2009527807A patent/JP5185274B2/ja active Active
- 2007-09-11 US US12/441,218 patent/US20090312284A1/en not_active Abandoned
- 2007-09-11 CA CA2659070A patent/CA2659070C/en active Active
- 2007-09-11 KR KR20097005123A patent/KR101489947B1/ko active IP Right Grant
- 2007-09-11 MX MX2009002925A patent/MX2009002925A/es active IP Right Grant
- 2007-09-11 EP EP07803397A patent/EP2066327B1/en active Active
-
2009
- 2009-03-05 IL IL197426A patent/IL197426A/en active IP Right Grant
-
2010
- 2010-01-19 HK HK10100549.4A patent/HK1136770A1/xx unknown
-
2013
- 2013-01-30 HR HRP20130080TT patent/HRP20130080T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO2008031817A3 (en) | 2008-11-20 |
| CA2659070C (en) | 2014-10-21 |
| MX2009002925A (es) | 2009-03-31 |
| EP2066327A2 (en) | 2009-06-10 |
| AU2007296256A1 (en) | 2008-03-20 |
| IL197426A0 (en) | 2009-12-24 |
| US20090312284A1 (en) | 2009-12-17 |
| EA020276B1 (ru) | 2014-10-30 |
| KR101489947B1 (ko) | 2015-02-04 |
| AU2007296256B2 (en) | 2013-05-30 |
| WO2008031817A2 (en) | 2008-03-20 |
| HK1136770A1 (en) | 2010-07-09 |
| JP5185274B2 (ja) | 2013-04-17 |
| EA200970284A1 (ru) | 2009-06-30 |
| CA2659070A1 (en) | 2008-03-20 |
| JP2010503636A (ja) | 2010-02-04 |
| EP2066327B1 (en) | 2012-11-14 |
| IL197426A (en) | 2014-12-31 |
| KR20090064383A (ko) | 2009-06-18 |
| PL2066327T3 (pl) | 2013-03-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20130080T1 (hr) | Inhibitori histonske deacetilaze sa spojenom aktivnosti protiv histonskih deacetilaza klase-i i klase-iib u kombinaciji sa inhibitorima proteasoma | |
| HRP20160327T1 (hr) | Čvrsti dozirni oblici fentanila s poboljšanom bukalnom apsorpcijom | |
| HRP20130057T1 (hr) | Lijeäśenje progresivne neurodegenerativne bolesti ibudilastom | |
| JP2006504795A5 (hr) | ||
| AR076835A1 (es) | Composiciones de comprimidos de desintegracion oral que comprenden combinaciones de drogas en dosis elevadas y reducidas. metodo. | |
| HRP20140780T4 (hr) | Amorfni i kristalinični oblik genz 112638 hemitartrata kao inhibitor glukozilceramid sintaze | |
| BR112012008317A2 (pt) | produto de liberação sustentada compreendendo uma combinação de uma amina não-opioide e uma droga anti-inflamatória não-esteroidal | |
| HRP20150644T1 (hr) | Metoda za lijeäśenje atrijalne fibrilacije | |
| JP2009504774A5 (hr) | ||
| RU2009118960A (ru) | Комбинации ацетаминофена/ибуппрофена | |
| HRP20201736T1 (hr) | Postupak liječenja diskinezije | |
| CO5650230A2 (es) | Composiciones estables de atorvastatina preparadas con granulacion en humedo | |
| ATE505203T1 (de) | Pharmazeutische kombination aus aliskiren und valsartan | |
| RU2012142811A (ru) | Фармацевтические композиции и пероральные дозированные формы пролекарства леводопы и способы применения | |
| RS54050B1 (en) | FORMULATIONS AND METHODS FOR THE TREATMENT OF AMYLOIDOSIS | |
| WO2008116601A3 (en) | Solid dosage forms comprising aliskiren and pharmaceutically acceptable salts thereof | |
| HRP20221344T1 (hr) | Novi pripravak acetaminofenskog spoja bez nuspojave po jetru | |
| JP2005519936A5 (hr) | ||
| RS52638B (en) | HISTONAL DEACETYLASE INHIBITORS WITH COMPOUND ACTIVITY AGAINST CLASS-I AND CLASS-IIB HISTONAL DEACETYLASES IN COMBINATION WITH PROTEAS INHIBITORS | |
| NZ611026A (en) | Pharmaceutical composition comprising citrate and bicarbonate salts, and use thereof for treating cystinuria | |
| DE602006012962D1 (de) | Pharmazeutische Zubereitungen von Ciprofloxacin | |
| JP2012041314A5 (hr) | ||
| HRP20110370T1 (hr) | Uporaba agomelatina za dobivanje lijeka u cilju liječenja smith-magenisovog sindroma | |
| RU2017113827A (ru) | Фармацевтический состав для уменьшения спазмов мочевого пузыря и способ его применения | |
| MX2022015742A (es) | Formas farmaceuticas osmoticas que comprenden deutetrabenazina y metodos de uso de las mismas. |